Author

R. M. Higashi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. N. Lane· 2 shared A. M. Intlekofer· 1 shared A. P. Sharda· 1 shared B. H. Segal· 1 shared C. M. Adams· 1 shared C. M. James· 1 shared D. A. Scott· 1 shared E. A. Repasky· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. N. Lane

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Biphasic response of CD8 T cell to asparagine restriction maximizes its metabolic fitness and antitumoral functionality

J. R. Gnanaprakasam, L. Liu, X. Chen, S. Kang, T. Wang, T. A. Cassel, C. M. Adams, R. M. Higashi, D. A. Scott, G. Xin, J. Yang, A. N. Lane, T. W. Fan, J. Zhang, R. Wang

This study shows that asparagine restriction induces a biphasic response in CD8 T cells, enhancing their metabolic fitness and antitumoral function through ATF4/NRF2-dependent mechanisms.

bioRxiv · Jul 18, 2022 · PreprintImmunology

ARS2-directed alternative splicing mediates CD28 driven T cell glycolysis and effector function

G. A. Holling, A. P. Sharda, M. M. Honikel, C. M. James, S. M. Lightman, G. Qiao, K. L. Singel, T. R. Emmons, T. Giridharan, S. Hou, A. M. Intlekofer, R. M. Higashi, T. W. M. Fan, A. N. Lane, K. H. Eng, , S. H. Olejniczak

This study shows ARS2 promotes CD28-driven T cell glycolysis and effector function through alternative splicing of Pkm2, enhancing anti-tumor immunity.

bioRxiv · May 7, 2021 · PreprintImmunology